Changes in urinary output due to concomitant administration of sacubitril/valsartan and atrial natriuretic peptide in patients with heart failure: a multicenter retrospective cohort study
Abstract Background Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor (ARNI) that inhibits the degradation of endogenous natriuretic peptides. Therefore, ARNIs may increase the efficacy of human atrial natriuretic peptide (hANP), a drug for acute heart failure, by mediating its ph...
Saved in:
Main Authors: | Tatsuki Yanagawa (Author), Yuki Asai (Author), Nobuyuki Zakoji (Author), Shingo Hosoe (Author), Yoshihiro Kondo (Author), Shinnosuke Ootsuki (Author), Hidekazu Kato (Author), Maria Aoki (Author), Yoshiaki Yamamoto (Author), Takanori Yamamoto (Author), Masaaki Takahashi (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Natriuretic peptide pathways in heart failure in the context of the analysis of the mechanism of action and potential usages of sacubitril/valsartan
by: Kamila Babkiewicz-Jahn, et al.
Published: (2024) -
Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022) -
Sacubitril/valsartan in real-life clinical practice
by: Yüksel Çavuşoğlu
Published: (2021) -
Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018) -
The concentration of maternal sacubitril/valsartan transferred into human milk is negligible
by: Sirin Falconi, et al.
Published: (2024)